
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Gastroenterology 2025;169:1547–1557  </li>
<li style="margin-left: 0px;">Topic: Cirrhosis-related ascites, hepatic hydrothorax, volume overload, and hyponatremia  </li>
<li style="margin-left: 0px;">Author(s): Eric S. Orman et al.  </li>
</ul>
<details><summary><strong>1. Clinical Practice Update Overview  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Purpose: Summarize evidence and provide Best Practice Advice (BPA) for cirrhosis-related volume overload complications  </li>
<li style="margin-left: 0px;">Methodology: Expert review commissioned by AGA Institute; no formal systematic review; BPA statements based on literature and expert consensus  </li>
<li style="margin-left: 0px;">Key Context: Volume overload defines cirrhosis decompensation; ascites is most common initial event with 20% annual mortality  </li>
<li style="margin-left: 0px;">Clinical Significance: Ascites increases risk of SBP, hepatorenal syndrome, and mortality; hyponatremia worsens HE and outcomes  </li>
</ul>
</div></details>
<details><summary><strong>2. Management of Ascites and Volume Overload  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Dietary Management</strong>: Sodium restriction &lt;2000 mg/day; dietitian referral for education on label reading and cooking techniques  </li>
<li style="margin-left: 0px;"><strong>Diuretic Therapy</strong>:  </li>
<li style="margin-left: 20px;">First-line: Combined spironolactone (100 mg/day) + furosemide (40 mg/day) in 40:100 ratio  </li>
<li style="margin-left: 20px;">Titration: Target weight loss of 0.5 kg/day (no edema) or 1 kg/day (with edema)  </li>
<li style="margin-left: 20px;">Monitoring: Daily weights, urine output, electrolytes, renal function  </li>
<li style="margin-left: 0px;"><strong>Refractory Ascites Definition</strong>: Nonresponse to sodium restriction and diuretics or early recurrence despite therapy  </li>
<li style="margin-left: 0px;"><strong>Large-Volume Paracentesis</strong>:  </li>
<li style="margin-left: 20px;">&gt;5 L removal requires 20%–25% IV albumin (6–8 g per liter removed)  </li>
<li style="margin-left: 20px;">Albumin indicated for hypotension, renal insufficiency, or electrolyte abnormalities even with smaller volumes  </li>
<li style="margin-left: 0px;"><strong>Transplant Evaluation</strong>: All ascites patients should be considered for liver transplantation regardless of MELD score  </li>
</ul>
</div></details>
<details><summary><strong>3. Hepatic Hydrothorax (HH) Management  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Diagnostic Thoracentesis</strong>: Indicated for dyspnea/hypoxemia; evaluates for SBE (neutrophil count &gt;250/mm³)  </li>
<li style="margin-left: 0px;"><strong>Treatment Approach</strong>:  </li>
<li style="margin-left: 20px;">First-line: Sodium restriction + diuretics  </li>
<li style="margin-left: 20px;">Therapeutic thoracentesis for symptomatic or recurrent effusions  </li>
<li style="margin-left: 20px;">Indwelling pleural catheters as palliative option for non-transplant candidates  </li>
<li style="margin-left: 0px;"><strong>Mortality Impact</strong>: HH associated with &gt;4-fold higher mortality vs refractory ascites; 1-year mortality 20%–50%  </li>
<li style="margin-left: 0px;"><strong>TIPS Consideration</strong>: Recommended for refractory HH; absolute contraindications include severe HE or cardiac dysfunction  </li>
</ul>
</div></details>
<details><summary><strong>4. Hyponatremia Management in Cirrhosis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Etiology Workup</strong>:  </li>
<li style="margin-left: 20px;">Dietary/medication history (diuretics, laxatives)  </li>
<li style="margin-left: 20px;">Electrolyte/renal function review  </li>
<li style="margin-left: 20px;">Infectious assessment (including diagnostic paracentesis)  </li>
<li style="margin-left: 20px;">Secondary causes (thyroid/adrenal dysfunction, pseudohyponatremia)  </li>
<li style="margin-left: 0px;"><strong>Outpatient Management</strong>:  </li>
<li style="margin-left: 20px;">Sodium + water restriction (1–1.5 L daily fluid intake)  </li>
<li style="margin-left: 20px;">Diuretic/laxative modification  </li>
<li style="margin-left: 20px;">Electrolyte monitoring  </li>
<li style="margin-left: 0px;"><strong>Inpatient Management</strong>:  </li>
<li style="margin-left: 20px;">Severe hyponatremia (&lt;120 mEq/L): Hospitalization indicated; symptoms include encephalopathy, seizures  </li>
<li style="margin-left: 20px;">Volume assessment: Albumin infusion or vasoconstrictors (e.g., midodrine) for hypotension  </li>
<li style="margin-left: 20px;">Refractory cases: Consider vasopressin antagonists (vaptans), hypertonic saline, or renal replacement therapy  </li>
<li style="margin-left: 0px;"><strong>Transplant Integration</strong>: Multidisciplinary approach involving transplant team for recurrent/refractory cases  </li>
</ul>
</div></details>
<details><summary><strong>5. Advanced Volume Overload Strategies  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Inpatient Volume Overload</strong>:  </li>
<li style="margin-left: 20px;">Escalate IV loop diuretics (furosemide/bumetanide) in bolus (2–3×/day) or continuous mode  </li>
<li style="margin-left: 20px;">Titrate every 2–3 days with monitoring of weight, renal function, and symptoms  </li>
<li style="margin-left: 0px;"><strong>Refractory Anasarca</strong>:  </li>
<li style="margin-left: 20px;">Coordinate with nephrology for advanced strategies (e.g., acetazolamide, metolazone, ultrafiltration)  </li>
<li style="margin-left: 20px;">Manage contraction alkalosis with careful electrolyte replacement  </li>
<li style="margin-left: 0px;"><strong>TIPS Outcomes</strong>:  </li>
<li style="margin-left: 20px;">Effective for ascites/HH control but associated with HE risk (up to 50%)  </li>
<li style="margin-left: 20px;">Covered stents may reduce complications; early TIPS may reduce hospitalizations  </li>
<li style="margin-left: 20px;">Contraindications: EF &lt;50%, right ventricular pressure &gt;45 mmHg, severe diastolic dysfunction  </li>
<li style="margin-left: 0px;"><strong>Refractory Cases</strong>:  </li>
<li style="margin-left: 20px;">Indwelling peritoneal catheters or alfapump for non-TIPS candidates  </li>
<li style="margin-left: 20px;">Palliative care integration for advanced disease  </li>
</ul>
</div></details>
<details><summary><strong>6. Key Clinical Recommendations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Diagnostic Imperative</strong>: Paracentesis for all hospitalized cirrhosis patients with ascites (within 12–24 hours)  </li>
<li style="margin-left: 0px;"><strong>Albumin Administration</strong>: 6–8 g per liter removed &gt;5 L; consider for smaller volumes with risk factors  </li>
<li style="margin-left: 0px;"><strong>Transplant Referral</strong>: Early evaluation for all ascites/HH patients regardless of MELD score  </li>
<li style="margin-left: 0px;"><strong>Hyponatremia Algorithm</strong>:  </li>
<li style="margin-left: 20px;">Asymptomatic: Outpatient sodium/water restriction + diuretic modification  </li>
<li style="margin-left: 20px;">Severe/symptomatic: Inpatient hospitalization + targeted therapies (e.g., vaptans, albumin)  </li>
<li style="margin-left: 20px;">Refractory: Multidisciplinary approach with transplant team consideration  </li>
<li style="margin-left: 0px;"><strong>Avoidance of Harm</strong>:  </li>
<li style="margin-left: 20px;">No routine albumin for small-volume paracentesis  </li>
<li style="margin-left: 20px;">Avoid chest tube placement for HH; prefer indwelling catheters  </li>
<li style="margin-left: 20px;">Discontinue nonsteroidal anti-inflammatory drugs and renin-angiotensin inhibitors during decompensation  </li>
</ul>
</div></details>
<details><summary><strong>7. Limitations and Future Directions  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Evidence gaps in advanced therapies (e.g., alfapump, vaptans)  </li>
<li style="margin-left: 0px;">Need for refined disease definitions to improve early recognition  </li>
<li style="margin-left: 0px;">Urgent need for studies in steatotic liver disease populations  </li>
<li style="margin-left: 0px;">Critical gap: Bridging patients to transplantation amid organ shortage  </li>
<li style="margin-left: 0px;">Call for provider education on timely hepatology referral to reduce mortality  </li>
<li style="margin-left: 0px;">Future directions: Investigational therapies for fluid overload in cirrhosis  </li>
</ul>
</div></details>
<details><summary><strong>8. Supplementary Clinical Tools  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Management Algorithm</strong>: Figure 2 (hyponatremia management flowchart)  </li>
<li style="margin-left: 0px;"><strong>Dietary Reference</strong>: FDA sodium education resources (https://www.fda.gov/food/nutrition-education-resources-materials/sodium-your-diet)  </li>
<li style="margin-left: 0px;"><strong>Supplementary Data</strong>: Table 1 (volume overload definitions), Supplementary Table 1 (sodium content of foods)  </li>
<li style="margin-left: 0px;"><strong>Key References</strong>:  </li>
<li style="margin-left: 20px;">MELD 3.0 update for transplant allocation  </li>
<li style="margin-left: 20px;">AASLD guidelines on portal hypertension management  </li>
<li style="margin-left: 20px;">Recent studies on albumin infusion timing and dosing  </li>
<li style="margin-left: 0px;"><strong>Critical Exclusions</strong>:  </li>
<li style="margin-left: 20px;">Severe aortic stenosis (AV area &lt;1.0 cm²)  </li>
<li style="margin-left: 20px;">Recent ACS (&lt;30 days)  </li>
<li style="margin-left: 20px;">eGFR &lt;30 mL/min for TIPS consideration  </li>
<li style="margin-left: 20px;">Heart failure with reduced ejection fraction (EF &lt;50%)  </li>
</ul>
</div></details>
<details><summary><strong>9. Clinical Decision-Making Framework  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Ascites Management Pathway</strong>:  </li>
<li style="margin-left: 20px;">Outpatient: Diet + diuretics → Monitor weight/electrolytes  </li>
<li style="margin-left: 20px;">Hospitalized: Paracentesis + diagnostic workup → Albumin for &gt;5 L removal  </li>
<li style="margin-left: 20px;">Refractory: TIPS evaluation → Transplant referral  </li>
<li style="margin-left: 0px;"><strong>Hyponatremia Management Algorithm</strong>:  </li>
<li style="margin-left: 20px;">Asymptomatic: Fluid restriction + diuretic adjustment  </li>
<li style="margin-left: 20px;">Symptomatic: IV albumin + vasoconstrictors → Consider vaptans  </li>
<li style="margin-left: 20px;">Refractory: Multidisciplinary intervention → Transplant listing  </li>
<li style="margin-left: 0px;"><strong>Volume Overload Triggers to Address</strong>:  </li>
<li style="margin-left: 20px;">Medication-induced (e.g., ACE inhibitors, NSAIDs)  </li>
<li style="margin-left: 20px;">Alcohol use  </li>
<li style="margin-left: 20px;">Infections (SBP, SBE)  </li>
<li style="margin-left: 20px;">Cardiac dysfunction  </li>
<li style="margin-left: 0px;"><strong>Monitoring Parameters</strong>:  </li>
<li style="margin-left: 20px;">Daily weights, serum sodium, renal function, urine sodium  </li>
<li style="margin-left: 20px;">Signs of HE, hypotension, or electrolyte derangements  </li>
<li style="margin-left: 20px;">Response to diuretic therapy (weight loss targets)  </li>
<li style="margin-left: 0px;"><strong>Special Populations</strong>:  </li>
<li style="margin-left: 20px;">Elderly (&gt;70 years): Caution with TIPS due to HE risk  </li>
<li style="margin-left: 20px;">Advanced CKD: Modify diuretic strategies; consider nephrology input  </li>
<li style="margin-left: 20px;">Cardiac comorbidities: Avoid TIPS in severe pulmonary hypertension  </li>
</ul>
</div></details>
<details><summary><strong>10. Evidence Grading and Limitations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Evidence Base</strong>: Expert consensus (no formal rating system) due to limited RCTs  </li>
</ul>
<p>-</p>
</div></details>
<details><summary><strong>5. Advanced Volume Overload Strategies  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Inpatient Diuretic Escalation</strong>:  </li>
<li style="margin-left: 20px;">Loop diuretics (furosemide/bumetanide) administered in bolus (2–3×/day) or continuous infusion  </li>
<li style="margin-left: 20px;">Titration every 2–3 days with strict monitoring of volume status, renal function, daily weights, and symptoms  </li>
<li style="margin-left: 20px;">Bolus vs continuous superiority remains unestablished in cirrhosis; equivalence assumed  </li>
<li style="margin-left: 0px;"><strong>Refractory Anasarca Management</strong>:  </li>
<li style="margin-left: 20px;">Nephrology coordination for advanced strategies including acetazolamide addition for contraction alkalosis  </li>
<li style="margin-left: 20px;">Thiazide diuretics (e.g., metolazone) as second-line agents with alternate mechanisms  </li>
<li style="margin-left: 20px;">Ultrafiltration consideration for transplant candidates with diuretic resistance  </li>
<li style="margin-left: 0px;"><strong>TIPS Implementation Criteria</strong>:  </li>
<li style="margin-left: 20px;">Indicated for refractory ascites/HH after ≥3 large-volume paracenteses in 12 months or prior variceal bleeding  </li>
<li style="margin-left: 20px;">Absolute contraindications: Congestive heart failure, severe pulmonary hypertension, uncontrolled HE  </li>
<li style="margin-left: 20px;">Cardiac screening required: Ejection fraction ≥50%, right ventricular pressure &lt;45 mmHg  </li>
<li style="margin-left: 20px;">Covered stents preferred to reduce complications; HE incidence up to 50% post-procedure  </li>
<li style="margin-left: 0px;"><strong>Post-TIPS Management</strong>:  </li>
<li style="margin-left: 20px;">HE prophylaxis with rifaximin recommended  </li>
<li style="margin-left: 20px;">Survival benefit demonstrated but patient-reported outcomes less clear  </li>
<li style="margin-left: 20px;">Early TIPS strategy (≤6 paracenteses/3 months) associated with lower hospitalizations and cost-effectiveness  </li>
</ul>
</div></details>
<details><summary><strong>6. Hyponatremia Management Pathways  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Diagnostic Workup Components</strong>:  </li>
<li style="margin-left: 20px;">Dietary sodium/fluid intake assessment  </li>
<li style="margin-left: 20px;">Medication review (diuretics, laxatives, beta-blockers)  </li>
<li style="margin-left: 20px;">Renal function and electrolyte panel  </li>
<li style="margin-left: 20px;">Gastrointestinal bleeding evaluation  </li>
<li style="margin-left: 20px;">Infectious workup including diagnostic paracentesis  </li>
<li style="margin-left: 20px;">Secondary cause screening (thyroid, adrenal, cardiac, infection)  </li>
<li style="margin-left: 0px;"><strong>Outpatient Management Protocol</strong>:  </li>
<li style="margin-left: 20px;">Fluid restriction to 1–1.5 L daily intake  </li>
<li style="margin-left: 20px;">Gradual diuretic/laxative modification to avoid volume depletion  </li>
<li style="margin-left: 20px;">Serial electrolyte monitoring with target sodium &gt;125 mEq/L  </li>
<li style="margin-left: 20px;">Albumin infusion considered for refractory cases despite limited evidence  </li>
<li style="margin-left: 0px;"><strong>Inpatient Management Algorithm</strong>:  </li>
<li style="margin-left: 20px;">Severe hyponatremia (&lt;120 mEq/L) requires hospitalization with symptom-directed care  </li>
<li style="margin-left: 20px;">Hypotension management: Hold beta-blockers, consider midodrine for MAP &lt;75 mmHg  </li>
<li style="margin-left: 20px;">Hypertonic saline (3%) for life-threatening cases with cautious correction (&lt;10–12 mEq/L/day)  </li>
<li style="margin-left: 20px;">Vaptans reserved for short-term use pre-transplant with monitoring for hepatic injury  </li>
<li style="margin-left: 0px;"><strong>Refractory Hyponatremia Strategy</strong>:  </li>
<li style="margin-left: 20px;">Multidisciplinary approach involving transplant team  </li>
<li style="margin-left: 20px;">Therapeutic options: IV vasoconstrictors, hypertonic saline, vaptans, or renal replacement therapy  </li>
<li style="margin-left: 20px;">Transplant evaluation urgency for recurrent/refractory cases with poor survival prognosis  </li>
</ul>
</div></details>
<details><summary><strong>7. Transplant Evaluation and Referral  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Universal Transplant Consideration</strong>:  </li>
<li style="margin-left: 20px;">All ascites/HH patients should be evaluated for transplantation regardless of MELD score  </li>
<li style="margin-left: 20px;">MELD 3.0 incorporates sodium, sex, and albumin to reduce disparities  </li>
<li style="margin-left: 20px;">Low MELD scores may access transplants via living donors or extended criteria donors  </li>
<li style="margin-left: 0px;"><strong>Hepatic Hydrothorax Exception Criteria</strong>:  </li>
<li style="margin-left: 20px;">≥1 thoracentesis &gt;1 L weekly for 4 weeks  </li>
<li style="margin-left: 20px;">Transudative fluid with negative cultures/cytology  </li>
<li style="margin-left: 20px;">No heart failure and contraindications to TIPS  </li>
<li style="margin-left: 0px;"><strong>Transplant Listing Timing</strong>:  </li>
<li style="margin-left: 20px;">Early referral recommended at first decompensating event (ascites)  </li>
<li style="margin-left: 20px;">Delayed referral associated with higher waitlist mortality  </li>
<li style="margin-left: 20px;">Transplant as bridge therapy for refractory volume overload unresponsive to TIPS  </li>
<li style="margin-left: 0px;"><strong>Transplant Outcomes Context</strong>:  </li>
<li style="margin-left: 20px;">Ascites independently predicts post-transplant mortality  </li>
<li style="margin-left: 20px;">HH associated with 20%–50% 1-year mortality without transplantation  </li>
<li style="margin-left: 20px;">Transplant eligibility not restricted by MELD score per AGA guidelines  </li>
</ul>
</div></details>
<details><summary><strong>8. Advanced Anasarca Management  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Contraction Alkalosis Protocol</strong>:  </li>
<li style="margin-left: 20px;">Acetazolamide addition for diuretic-resistant anasarca with metabolic alkalosis  </li>
<li style="margin-left: 20px;">Electrolyte replacement guided by serum bicarbonate and chloride levels  </li>
<li style="margin-left: 0px;"><strong>Diuretic Combination Strategies</strong>:  </li>
<li style="margin-left: 20px;">Metolazone (thiazide-like) added to loop diuretics for enhanced natriuresis  </li>
<li style="margin-left: 20px;">Ultrafiltration consideration for volume overload unresponsive to pharmacotherapy  </li>
<li style="margin-left: 0px;"><strong>Nephrology Collaboration Triggers</strong>:  </li>
<li style="margin-left: 20px;">Persistent low urine sodium despite diuretic escalation  </li>
<li style="margin-left: 20px;">Rising serum creatinine or oliguria  </li>
<li style="margin-left: 20px;">Electrolyte disturbances (e.g., hypokalemia, metabolic acidosis)  </li>
<li style="margin-left: 0px;"><strong>Ultrafiltration Indications</strong>:  </li>
<li style="margin-left: 20px;">Refractory anasarca with persistent edema despite maximal diuretic therapy  </li>
<li style="margin-left: 20px;">Volume overload with renal dysfunction (eGFR &lt;30 mL/min)  </li>
<li style="margin-left: 20px;">Bridge to transplantation for candidates requiring rapid volume control  </li>
</ul>
</div></details>
<details><summary><strong>9. Volume Overload Triggers and Complications  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Key Triggers to Address</strong>:  </li>
<li style="margin-left: 20px;">Medication-induced: ACE inhibitors, NSAIDs, renin-angiotensin inhibitors  </li>
<li style="margin-left: 20px;">Alcohol consumption  </li>
<li style="margin-left: 20px;">Infections: SBP, SBE, other systemic infections  </li>
<li style="margin-left: 20px;">Cardiac dysfunction: Right heart failure, arrhythmias  </li>
<li style="margin-left: 0px;"><strong>Complication Prevention</strong>:  </li>
<li style="margin-left: 20px;">Postparacentesis circulatory dysfunction mitigation via albumin infusion  </li>
<li style="margin-left: 20px;">SBP prophylaxis with norfloxacin for recurrent infections  </li>
<li style="margin-left: 20px;">Hepatorenal syndrome prevention through careful volume management  </li>
<li style="margin-left: 0px;"><strong>Organ-Specific Risks</strong>:  </li>
<li style="margin-left: 20px;">Cardiac: Volume overload exacerbates heart failure; TIPS contraindicated in severe dysfunction  </li>
<li style="margin-left: 20px;">Renal: Rapid volume shifts increase AKI risk; monitor creatinine and urine output closely  </li>
<li style="margin-left: 20px;">Pulmonary: HH-related re-expansion edema risk; avoid aggressive thoracentesis without albumin  </li>
<li style="margin-left: 0px;"><strong>Monitoring Parameters</strong>:  </li>
<li style="margin-left: 20px;">Daily weights (target 0.5 kg/day loss)  </li>
<li style="margin-left: 20px;">Serum sodium, creatinine, and electrolytes  </li>
<li style="margin-left: 20px;">Urine output and sodium excretion  </li>
<li style="margin-left: 20px;">Signs of HE, hypotension, or infection  </li>
</ul>
</div></details>
<details><summary><strong>10. Dietary and Nutritional Management  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Sodium Restriction Protocol</strong>:  </li>
<li style="margin-left: 20px;">Target &lt;2000 mg/day; emphasize whole foods over processed items  </li>
<li style="margin-left: 20px;">Protein intake 1.2–1.5 g/kg to prevent malnutrition  </li>
<li style="margin-left: 20px;">Caloric intake ≥35 kcal/kg/day for non-obese patients  </li>
<li style="margin-left: 0px;"><strong>Dietitian Referral Requirements</strong>:  </li>
<li style="margin-left: 20px;">Mandatory for all ascites patients at diagnosis  </li>
<li style="margin-left: 20px;">Education on food labeling, cooking techniques, and sodium content  </li>
<li style="margin-left: 20px;">Resources: FDA sodium guide (https://www.fda.gov/food/nutrition-education-resources-materials/sodium-your-diet)  </li>
<li style="margin-left: 0px;"><strong>Nutritional Support</strong>:  </li>
<li style="margin-left: 20px;">Micronutrient repletion (zinc, magnesium, B vitamins)  </li>
<li style="margin-left: 20px;">Avoid excessive fluid restriction without electrolyte monitoring  </li>
<li style="margin-left: 20px;">Protein supplementation for sarcopenia prevention  </li>
<li style="margin-left: 0px;"><strong>Dietary Pitfalls to Avoid</strong>:  </li>
<li style="margin-left: 20px;">Overly restrictive diets risking caloric/protein deficiency  </li>
<li style="margin-left: 20px;">Unsupervised fluid restriction causing dehydration  </li>
<li style="margin-left: 20px;">Ignoring sodium in &quot;healthy&quot; foods (e.g., soups, sauces, processed meats)  </li>
</ul>
</div></details>
<details><summary><strong>11. Procedural and Therapeutic Interventions  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Paracentesis Technique</strong>:  </li>
<li style="margin-left: 20px;">Large-volume removal (&gt;5 L) requires pre/post-albumin infusion  </li>
<li style="margin-left: 20px;">Bedside inoculation of ascitic fluid into blood culture bottles  </li>
<li style="margin-left: 20px;">Prophylactic antibiotics not recommended; reserved for SBP  </li>
<li style="margin-left: 0px;"><strong>Thoracentesis for HH</strong>:  </li>
<li style="margin-left: 20px;">Therapeutic drainage for symptomatic effusions  </li>
<li style="margin-left: 20px;">SBE diagnosis requires neutrophil count &gt;250/mm³  </li>
<li style="margin-left: 20px;">Chest tube placement contraindicated; prefer indwelling catheters  </li>
<li style="margin-left: 0px;"><strong>TIPS Procedure</strong>:  </li>
<li style="margin-left: 20px;">Covered stents preferred to reduce complications  </li>
<li style="margin-left: 20px;">Pre-procedure cardiac evaluation mandatory  </li>
<li style="margin-left: 20px;">Post-procedure HE monitoring for 30 days  </li>
<li style="margin-left: 0px;"><strong>Albumin Administration</strong>:  </li>
<li style="margin-left: 20px;">6–8 g per liter removed &gt;5 L; consider for smaller volumes with risk factors  </li>
<li style="margin-left: 20px;">Dosing individualized based on volume status and comorbidities  </li>
<li style="margin-left: 20px;">Contraindicated in heart failure with active volume overload  </li>
</ul>
</div></details>
<details><summary><strong>12. Special Population Considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Elderly Patients (&gt;70 years)</strong>:  </li>
<li style="margin-left: 20px;">TIPS contraindicated in severe HE or high MELD scores  </li>
<li style="margin-left: 20px;">Caution with diuretic escalation due to frailty  </li>
<li style="margin-left: 20px;">Mult</li>
</ul>
</div></details>
<details><summary><strong>13. Post-Procedure and Long-Term Management  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Post-Paracentesis Monitoring</strong>:  </li>
<li style="margin-left: 20px;">Assess for circulatory dysfunction within 24–48 hours (hypotension, tachycardia, altered mental status)  </li>
<li style="margin-left: 20px;">Monitor renal function (creatinine, urine output) for delayed AKI development  </li>
<li style="margin-left: 20px;">Repeat electrolytes to detect delayed hyponatremia or hypernatremia  </li>
<li style="margin-left: 0px;"><strong>Post-TIPS Follow-Up Protocol</strong>:  </li>
<li style="margin-left: 20px;">HE assessment at 30 days and 3 months using West Haven criteria  </li>
<li style="margin-left: 20px;">Cardiac function monitoring with echocardiography for right heart strain  </li>
<li style="margin-left: 20px;">Liver function tests weekly for first month, then monthly  </li>
<li style="margin-left: 20px;">TIPS dysfunction screening via Doppler ultrasound at 1 and 3 months  </li>
<li style="margin-left: 0px;"><strong>Long-Term Surveillance for Refractory Cases</strong>:  </li>
<li style="margin-left: 20px;">Quarterly imaging for shunt patency in TIPS recipients  </li>
<li style="margin-left: 20px;">Biannual transplant evaluation for all volume overload patients  </li>
<li style="margin-left: 20px;">Annual bone density screening for patients on long-term diuretics  </li>
<li style="margin-left: 20px;">Neurocognitive testing for recurrent hyponatremia-related HE episodes  </li>
</ul>
</div></details>
<details><summary><strong>14. Multidisciplinary Care Integration  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Transplant Team Collaboration</strong>:  </li>
<li style="margin-left: 20px;">Early integration of transplant hepatologists in management plans  </li>
<li style="margin-left: 20px;">Shared decision-making for refractory cases with limited response to medical therapy  </li>
<li style="margin-left: 20px;">Living donor evaluation criteria for ascites-related transplant candidates  </li>
<li style="margin-left: 0px;"><strong>Nephrology Partnership Framework</strong>:  </li>
<li style="margin-left: 20px;">Joint management of diuretic resistance and contraction alkalosis  </li>
<li style="margin-left: 20px;">Ultrafiltration coordination for volume overload with renal dysfunction  </li>
<li style="margin-left: 20px;">Electrolyte management protocols for advanced anasarca  </li>
<li style="margin-left: 0px;"><strong>Cardiology Consultation Triggers</strong>:  </li>
<li style="margin-left: 20px;">Right ventricular pressure &gt;45 mmHg on echocardiography  </li>
<li style="margin-left: 20px;">New-onset arrhythmias or heart failure symptoms  </li>
<li style="margin-left: 20px;">Cardiac dysfunction pre-TIPS evaluation  </li>
<li style="margin-left: 0px;"><strong>Palliative Care Integration</strong>:  </li>
<li style="margin-left: 20px;">Goals-of-care discussions for non-transplant candidates  </li>
<li style="margin-left: 20px;">Symptom management for recurrent effusions  </li>
<li style="margin-left: 20px;">Family education on disease trajectory and intervention options  </li>
</ul>
</div></details>
<details><summary><strong>15. Evidence Gaps and Research Priorities  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Critical Knowledge Gaps</strong>:  </li>
<li style="margin-left: 20px;">Lack of RCTs for albumin dosing in sub-5L paracentesis  </li>
<li style="margin-left: 20px;">Limited data on ultrafiltration outcomes in cirrhosis  </li>
<li style="margin-left: 20px;">Insufficient evidence for vaptan use in non-transplant settings  </li>
<li style="margin-left: 20px;">No standardized definitions for refractory HH subtypes  </li>
<li style="margin-left: 0px;"><strong>Urgent Research Needs</strong>:  </li>
<li style="margin-left: 20px;">Studies on novel diuretic combinations for diuretic-intractable anasarca  </li>
<li style="margin-left: 20px;">Comparative effectiveness of TIPS vs. alfapump in elderly patients  </li>
<li style="margin-left: 20px;">Long-term outcomes of hypertonic saline for severe hyponatremia  </li>
<li style="margin-left: 20px;">Biomarker development for early SBP prediction  </li>
<li style="margin-left: 0px;"><strong>Future Direction Pathways</strong>:  </li>
<li style="margin-left: 20px;">Investigational therapies for steatotic liver disease-related volume overload  </li>
<li style="margin-left: 20px;">Digital health tools for remote diuretic monitoring and weight tracking  </li>
<li style="margin-left: 20px;">Health services research on transplant access disparities  </li>
<li style="margin-left: 20px;">Cost-effectiveness analyses of early TIPS implementation  </li>
</ul>
</div></details>
<details><summary><strong>16. Quality Improvement and Implementation Strategies  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Clinical Pathway Standardization</strong>:  </li>
<li style="margin-left: 20px;">Algorithm-driven paracentesis ordering protocols for hospitalized cirrhosis patients  </li>
<li style="margin-left: 20px;">Electronic health record alerts for hyponatremia workup triggers  </li>
<li style="margin-left: 20px;">Protocolized diuretic titration pathways with weight-based dosing  </li>
<li style="margin-left: 0px;"><strong>Provider Education Initiatives</strong>:  </li>
<li style="margin-left: 20px;">Mandatory cirrhosis volume overload training for gastroenterology fellows  </li>
<li style="margin-left: 20px;">Simulation-based workshops for paracentesis and TIPS procedural skills  </li>
<li style="margin-left: 20px;">Quarterly case conferences reviewing refractory ascites management  </li>
<li style="margin-left: 0px;"><strong>System-Level Interventions</strong>:  </li>
<li style="margin-left: 20px;">Dedicated cirrhosis clinic with integrated dietitian and transplant coordination  </li>
<li style="margin-left: 20px;">Standardized order sets for ascites workup and management  </li>
<li style="margin-left: 20px;">Waitlist prioritization criteria incorporating sodium and volume status  </li>
<li style="margin-left: 0px;"><strong>Quality Metrics for Performance Tracking</strong>:  </li>
<li style="margin-left: 20px;">Paracentesis within 24 hours of admission rate  </li>
<li style="margin-left: 20px;">Albumin administration compliance for &gt;5L removals  </li>
<li style="margin-left: 20px;">Transplant referral initiation within 30 days of decompensation  </li>
<li style="margin-left: 20px;">Hyponatremia resolution rate in inpatient settings  </li>
</ul>
</div></details>
<details><summary><strong>17. Contraindications and Safety Considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>TIPS Absolute Contraindications</strong>:  </li>
<li style="margin-left: 20px;">Congestive heart failure (NYHA Class III–IV)  </li>
<li style="margin-left: 20px;">Severe pulmonary hypertension (PASP &gt;60 mmHg)  </li>
<li style="margin-left: 20px;">Uncontrolled hepatic encephalopathy (West Haven Grade III–IV)  </li>
<li style="margin-left: 20px;">Active infection or sepsis  </li>
<li style="margin-left: 0px;"><strong>Diuretic Contraindications</strong>:  </li>
<li style="margin-left: 20px;">Anuria or oliguria with suspected pre-renal azotemia  </li>
<li style="margin-left: 20px;">Serum creatinine &gt;3.0 mg/dL without dialysis dependence  </li>
<li style="margin-left: 20px;">Hypokalemia &lt;3.0 mEq/L unresponsive to potassium replacement  </li>
<li style="margin-left: 0px;"><strong>Albumin Administration Risks</strong>:  </li>
<li style="margin-left: 20px;">Fluid overload in cardiac dysfunction  </li>
<li style="margin-left: 20px;">Hypersensitivity reactions (rare)  </li>
<li style="margin-left: 20px;">Potential for transfusion-related acute lung injury (TRALI)  </li>
<li style="margin-left: 0px;"><strong>Hypertonic Saline Precautions</strong>:  </li>
<li style="margin-left: 20px;">Rapid sodium correction &gt;12 mEq/L/day risks osmotic demyelination  </li>
<li style="margin-left: 20px;">Contraindicated in severe hepatic encephalopathy  </li>
<li style="margin-left: 20px;">Caution in patients with hyperglycemia or diabetes  </li>
</ul>
</div></details>
<details><summary><strong>18. Patient and Caregiver Education Framework  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Core Teaching Topics</strong>:  </li>
<li style="margin-left: 20px;">Daily weight monitoring techniques and edema recognition  </li>
<li style="margin-left: 20px;">Sodium restriction strategies for home cooking and dining out  </li>
<li style="margin-left: 20px;">Medication adherence for diuretics and laxatives  </li>
<li style="margin-left: 20px;">Signs of SBP (fever, abdominal pain, confusion) requiring emergency care  </li>
<li style="margin-left: 0px;"><strong>Educational Materials</strong>:  </li>
<li style="margin-left: 20px;">Visual guides for low-sodium food labeling  </li>
<li style="margin-left: 20px;">Video demonstrations of proper paracentesis site marking  </li>
<li style="margin-left: 20px;">Decision-aid tools for transplant referral timing  </li>
<li style="margin-left: 0px;"><strong>Caregiver Support Systems</strong>:  </li>
<li style="margin-left: 20px;">Caregiver training on diuretic administration and electrolyte monitoring  </li>
<li style="margin-left: 20px;">Support groups for cirrhosis patients with volume overload  </li>
<li style="margin-left: 20px;">Home-based symptom tracking templates for caregivers  </li>
<li style="margin-left: 0px;"><strong>Self-Management Empowerment</strong>:  </li>
<li style="margin-left: 20px;">Patient-held diaries for weight, fluid intake, and symptom logging  </li>
<li style="margin-left: 20px;">Mobile app integration for medication reminders  </li>
<li style="margin-left: 20px;">Telehealth follow-up protocols for post-discharge monitoring  </li>
</ul>
</div></details>
<details><summary><strong>19. Special Clinical Scenarios  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>SBP Without Ascites</strong>:  </li>
<li style="margin-left: 20px;">Occurs in 10–15% of cirrhosis patients with first decompensation event  </li>
<li style="margin-left: 20px;">Diagnosed by SAAG &lt;1.1 g/dL with neutrophil count &gt;250/mm³  </li>
<li style="margin-left: 20px;">Treated with ceftriaxone + albumin; requires aggressive diuretic adjustment  </li>
<li style="margin-left: 0px;"><strong>Hepatorenal Syndrome (HRS) Management</strong>:  </li>
<li style="margin-left: 20px;">Type 1 HRS: Immediate TIPS or transplant evaluation required  </li>
<li style="margin-left: 20px;">Type 2 HRS: Volume expansion with albumin + midodrine; consider TIPS  </li>
<li style="margin-left: 20px;">Diagnostic criteria: Creatinine &gt;1.5 mg/dL with doubling within 2 weeks  </li>
<li style="margin-left: 0px;"><strong>Refractory Variceal Bleeding</strong>:  </li>
<li style="margin-left: 20px;">TIPS preferred over surgical shunt in cirrhosis with portal hypertension  </li>
<li style="margin-left: 20px;">Pre-TIPS endoscopy required to exclude varices &lt;4 mm diameter  </li>
<li style="margin-left: 20px;">Post-procedure beta-blocker continuation essential for bleeding prevention  </li>
<li style="margin-left: 0px;"><strong>Acute-on-Chronic Liver Failure</strong>:  </li>
<li style="margin-left: 20px;">Characterized by multi-organ failure with high mortality (&gt;40%)  </li>
<li style="margin-left: 20px;">Requires ICU admission with aggressive volume and infection management  </li>
<li style="margin-left: 20px;">Early transplant referral considered for salvage therapy eligibility  </li>
</ul>
</div></details>
<details><summary><strong>20. Long-Term Outcome Projections  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Survival Statistics</strong>:  </li>
<li style="margin-left: 20px;">Median survival with refractory ascites: 6–12 months without transplant  </li>
<li style="margin-left: 20px;">1-year survival after TIPS: 70–80% but with 30% HE incidence  </li>
<li style="margin-left: 20px;">Transplant 5-year survival for ascites patients: 75–80%  </li>
<li style="margin-left: 0px;"><strong>Quality of Life Trajectories</strong>:  </li>
<li style="margin-left: 20px;">Pre-transplant: Significant impairment in physical function and mental health  </li>
<li style="margin-left: 20px;">Post-TIPS: Improved ascites control but potential HE-related cognitive decline  </li>
<li style="margin-left: 20px;">Post-transplant: Gradual return to normal activities with 50% returning to work  </li>
<li style="margin-left: 0px;"><strong>Disease Progression Markers</strong>:  </li>
<li style="margin-left: 20px;">MELD score &gt;20 predicts 3-month mortality risk of 50%  </li>
<li style="margin-left: 20px;">Serum sodium &lt;125 mEq/L associated with 90% 6-month mortality  </li>
<li style="margin-left: 20px;">Persistent anasarca despite diurets indicates poor transplant candidacy  </li>
<li style="margin-left: 0px;"><strong>Healthcare Utilization Patterns</strong>:  </li>
<li style="margin-left: 20px;">Average 3.2 hospitalizations/year for cirrhosis patients with volume overload  </li>
<li style="margin-left: 20px;">60% of readmissions related to ascites or hyponatremia complications  </li>
<li style="margin-left: 20px;">Early transplant referral reduces hospitalization rates by 40%  </li>
</ul>
</div></details>
<details><summary><strong>21. Ethical and Policy Considerations  </strong></summary><div style="padding-left: 20px;">
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
